C5ORF34 anticorps (AA 1-100) (Biotin)

N° du produit ABIN1701100

Détail du produit anti-C5ORF34 anticorps (Biotin)

Antigène: C5ORF34 (Chromosome 5 Open Reading Frame 34 (C5ORF34))

Épitope: AA 1-100

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp C5ORF34 est conjugé à/à la Biotin

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Réactivité croisée: Humain

Homologie: Mouse,Rat,Dog,Pig,Horse

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human C5orf34

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur C5ORF34

Antigène: C5ORF34 (Chromosome 5 Open Reading Frame 34 (C5ORF34))

Autre désignation: C5orf34 (C5ORF34 Produits)

Synonymes: anticorps chromosome 5 open reading frame 34, anticorps C5orf34

Sujet:

Synonyms: C5orf34, CE034_HUMAN, FLJ32363, Uncharacterized protein C5orf34.

Background: C5orf34 is a With 181 million base pairs encoding around 1,000 genes, chromosome 5 is about 6 % of human genomic DNA. It is associated with Cockayne syndrome through the ERCC8 gene and familial adenomatous polyposis through the adenomatous polyposis coli (APC) tumor suppressor gene. Treacher Collins syndrome is also chromosome 5 associated and is caused by insertions or deletions within the TCOF1 gene. Deletion of the p arm of chromosome 5 leads to Cri du chat syndrome. Deletion of 5q or chromosome 5 altogether is common in therapy-related acute myelogenous leukemias and myelodysplastic syndrome. The C5orf34 gene product has been provisionally designated C5orf34 pending further characterization.